• Submit to Antibodies Login Register
• MDPI
• Journals A-Z
• For Authors
• For Editors
• For Librarians
• About
• Open Access Policy

• Abstract
• Full-Text PDF [623 KB]
• Full-Text XML
• Article Versions Notes

• Article Statistics
• Google Scholar
• Order Reprints

• Cite this article
• Export to BibTeX
• Export to EndNote

• [+] on DOAJ
• Stamova, S
• Koristka, S
• Keil, J
• Arndt, C
• Feldmann, A
• Michalk, I
• Bartsch, H
• Bippes, C
• Schmitz, M
• Cartellieri, M
• Bachmann, M
• [+] on Google Scholar
• Stamova, S
• Koristka, S
• Keil, J
• Arndt, C
• Feldmann, A
• Michalk, I
• Bartsch, H
• Bippes, C
• Schmitz, M
• Cartellieri, M
• Bachmann, M
• [+] on PubMed
• Stamova, S
• Koristka, S
• Keil, J
• Arndt, C
• Feldmann, A
• Michalk, I
• Bartsch, H
• Bippes, C
• Schmitz, M
• Cartellieri, M
• Bachmann, M

•  CiteULike
•  Facebook
•  Mendeley
•  Twitter
• More services

Open AccessThis article is

• freely available
• re-usable

Antibodies 2012, 1(2), 172-198; doi:10.3390/antib1020172

Review

Cancer Immunotherapy by Retargeting of Immune Effector Cells via Recombinant Bispecific Antibody Constructs

Slava Stamova ^1,†, Stefanie Koristka ¹, Juliane Keil ¹, Claudia Arndt ¹, Anja Feldmann ¹, Irene Michalk ¹, Holger Bartsch ¹, Claudia C. Bippes ¹, Marc Schmitz ¹, Marc Cartellieri ¹ and Michael Bachmann ^1,2,*

¹ Institute of Immunology, Medical Faculty Carl Gustav Carus, Technical University Dresden, Fetscherstr. 74, 01307 Dresden, Germany ² The DFG research Center and Cluster of Excellence for Regenerative Therapies Dresden, Germany ^† Present address: Translational Immunology Unit, German Cancer Research Center, NCT Building, Im Neuenheimer Feld 460, 69120 Heidelberg, Germany.

* Author to whom correspondence should be addressed.

Received: 24 May 2012; in revised form: 27 June 2012 / Accepted: 10 July 2012 / Published: 18 July 2012

(This article belongs to the Special Issue Bispecific Antibodies for Dual Targeting Strategies)

Download PDF Full-Text [623 KB, uploaded 18 July 2012 13:50 CEST]

Abstract: Immunotherapy has emerged as an alternative strategy to treat malignancies in addition to conventional radio- and chemotherapy. There has been a plethora of evidence that the immune system is able to control tumor outgrowth and a number of strategies have been put forward to utilize this ability for immunotherapy. However, some of these strategies have not been very efficient and their success has been limited by tumor evasion mechanisms. A promising approach to engage effector cells of the immune system overcoming some of the escape mechanisms has been introduced more than two decades ago. This approach is based on bispecific antibodies. Here we summarize the evolution of bispecific antibodies, their improvement, remaining obstacles and some controversial reports.

Keywords: cancer immunotherapy; monoclonal antibodies; antibody engineering; bispecific antibodies

Article Statistics

Citations to this Article

Cite This Article